Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - Authors' reply

Affiliations

¹ Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: dmhalperin@mdanderson.org.
² Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Comment

Daniel M Halperin et al. Lancet Oncol. 2017 Jun.

. 2017 Jun;18(6):e300.

doi: 10.1016/S1470-2045(17)30347-9.

¹ Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: dmhalperin@mdanderson.org.
² Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

No abstract available

Comment on

Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC. Halperin DM, et al. Lancet Oncol. 2017 Apr;18(4):525-534. doi: 10.1016/S1470-2045(17)30110-9. Epub 2017 Feb 24. Lancet Oncol. 2017. PMID: 28238592 Free PMC article.
Incidence and prognosis of carcinoid syndrome: hormones or tumour burden?
Zandee WT, de Herder WW, Jann H. Zandee WT, et al. Lancet Oncol. 2017 Jun;18(6):e299. doi: 10.1016/S1470-2045(17)30335-2. Lancet Oncol. 2017. PMID: 28593854 No abstract available.